ClinicalTrials.gg
CompletedNCT03732638Updated Jun 7, 2024Results posted

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

A Phase 2/3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 93 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by Pfizer · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,590
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
5th of 32
1,590 · median 618
Started
2018
with 1 other
Phase 2/3
2 of 32
none open now
Registered
7th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 2/3, and was the 7th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Prevention
  • Prophylaxis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:

    1. Age of onset of migraines prior to 50 years of age
    2. Migraine attacks, on average, lasting 4 - 72 hours if untreated
    3. Per subject report, 4 - 18 migraine attacks of moderate to severe intensity per month within the last 3 months prior to the Screening Visit
    4. 6 or more migraine days during the Observation Period
    5. Not more than 18 headache days during the Observation Period
    6. Ability to distinguish migraine attacks from tension/cluster headaches
    7. Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subject with a history of disease
  2. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening
  3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to screening).
  4. Subjects with major depressive episode within the last 12 months, major depressive disorder or any anxiety disorder requiring more than 1 medication for each disorder. Medications to treat major depressive disorder or an anxiety disorder must have been at a stable dose for at least 3 months prior to the Screening visit.
  5. Subjects with other pain syndromes, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments
  6. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease that causes malabsorption
  7. ≥ 33 kg/m2
  8. Subject has current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder
  9. History of gallstones or cholecystectomy.
  10. The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,590 participants (actual)

Study arms

  • Experimental
    DBT Rimegepant/OL Rimegepant

    DBT Phase (Weeks 1 through 12): Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks. OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (as needed \[PRN\] dosing). After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation.

    Drug: Rimegepant

  • Placebo comparator
    DBT Placebo/OL Rimegepant

    DBT Phase (Weeks 1 through 12): Participants received a single oral dose of placebo matching to rimegepant tablet EOD for 12 weeks. OLE Phase (Weeks 13 through 64): Participants who continued to meet study entry criteria and had acceptable laboratory test results per protocol, entered the OLE phase and received a single oral dose of rimegepant 75 mg tablet EOD for 52 weeks. If participants had a migraine on a day that they were not scheduled to dose with rimegepant, they could take one tablet of rimegepant 75 mg on that calendar day to treat a migraine (PRN dosing). After completing the OLE phase, participants had follow-up safety visits 2 and 8 weeks after the End-of-Treatment (EOT) visit. Participants who did not complete the DBT phase and/or did not enter or complete the OLE phase were to complete the EOT visit, the 2-week follow-up safety visit, and the 8-week follow-up safety visit after their early discontinuation.

    Drug: Rimegepant · Drug: Placebo

Interventions

  • Rimegepant 75 mg tablet EOD

    Also known as: BHV-3000

  • DrugPlacebo

    Placebo tablet to match rimegepant tablet EOD

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase

    A migraine day: any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache: a migraine with or without aura, lasting for ≥30 minutes, and meeting at least 1 of the following criteria (a and/or b): a) ≥2 of the following: unilateral location, pulsating quality, moderate to severe pain intensity, aggravation by or causing avoidance of routine physical activity; b) ≥1 of the following: nausea and/or vomiting, photophobia, and phonophobia. If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the last 4 weeks of the DBT phase (Weeks 9 to 12) minus number of monthly migraine days during the OP.

    Time frame: OP and Weeks 9 to 12 of the DBT phase

Secondary outcomes

  1. Number of Participants Who Had ≥ 50% Reduction in Moderate or Severe Migraine Days Per Month in the Last 4 Weeks of the DBT Phase

    A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. A moderate or severe migraine day was a migraine day of moderate or severe pain intensity. Months were defined as 28-day intervals. A reduction of at least 50% in the mean number of moderate or severe monthly migraine days was determined if the number of moderate or severe monthly migraine days in the last 4 weeks of the DBT (Weeks 9 to 12) was less than or equal to half (50%) of the number of moderate or severe monthly migraine days in the OP.

    Time frame: OP and Weeks 9 to 12 of the DBT phase

  2. Change From Baseline in the Mean Number of Migraine Days Per Month Over the Entire Course of the DBT Phase

    A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the DBT phase (Weeks 1 to 12) minus the number of monthly migraine days during the OP.

    Time frame: OP and Weeks 1 to 12 of the DBT phase

  3. Frequency of Use of Rescue Medication Days Per Month in the Last Month of the DBT Phase

    A rescue medication day was a day on which the participant took triptan, ergotamine, or other permitted medication to acutely treat headache or aura. Months were defined as 28-day intervals.

    Time frame: Weeks 9 to 12 of the DBT phase

  4. Change From Baseline in the Mean Number of Total Migraine Days Per Month in the First Month of the DBT Phase

    A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the first 4 weeks of the DBT phase (Weeks 1 to 4) minus the number of monthly migraine days during the OP.

    Time frame: OP and Weeks 1 to 4 of the DBT phase

  5. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation in the DBT Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

    Time frame: Weeks 1 to 12 of the DBT phase

  6. Number of Participants With AEs, SAEs, AEs Leading to Study Drug Discontinuation in the OLE Phase

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

    Time frame: OLE Phase (Weeks 13 through 64)

  7. Number of Participants With Clinically Significant Laboratory Abnormalities in the DBT Phase

    Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events (CTCAE) Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the DBT phase to be included for a given parameter.

    Time frame: Weeks 1 to 12 of the DBT phase

  8. Number of Participants With Clinically Significant Laboratory Abnormalities in the OLE Phase

    Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in CTCAE Version 5.0 (2017) if available; otherwise, according to DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the OLE phase to be included for a given parameter.

    Time frame: OLE Phase (Weeks 13 through 64)

  9. Number of Participants With Elevations of AST or ALT > 3 x Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) > 2 x ULN During the DBT Phase

    Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the OLE phase to be included.

    Time frame: Weeks 1 to 12 of the DBT phase

  10. Percentage of Participants With Elevations of AST or ALT > 3 x ULN Concurrent With TBL > 2 x ULN During the OLE Phase

    Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the DBT phase to be included.

    Time frame: OLE Phase (Weeks 13 through 64)

  11. Number of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the DBT Phase

    Hepatic AEs were defined as all preferred terms in the DBT phase under the "Hepatic Disorders" Standardized Medical Dictionary (Version 21.1) for Regulatory Activities Query (SMQ), except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.

    Time frame: Weeks 1 to 12 of the DBT phase

  12. Number of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the OLE Phase

    Hepatic AEs were defined as all preferred terms in the OLE phase under the "Hepatic Disorders" SMQ, except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.

    Time frame: OLE Phase (Weeks 13 through 64)

  13. Mean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase

    The Migraine Specific Quality of Life (MSQoL) is a self-administered, 14-item instrument that has been validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.

    Time frame: Baseline, Week 12 of the DBT Phase

  14. Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase

    The Migraine Disability Assessment (MIDAS) is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.

    Time frame: Baseline, Week 12 of the DBT Phase

07

Results

Posted Aug 9, 2021

Participant flow

The study was conducted at 92 sites in the United States.

DBT Phase (Weeks 1 to 12)
Participant flow — DBT Phase (Weeks 1 to 12)
MilestoneDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
Started370371
Completed316310
Not completed5461
Withdrew: Adverse event52
Withdrew: Eligibility failure due to baseline laboratory values813
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up1912
Withdrew: Non-compliance65
Withdrew: Physician decision01
Withdrew: Protocol deviation45
Withdrew: Withdrawal by subject1122
OLE Phase (Weeks 13 to 64)
Participant flow — OLE Phase (Weeks 13 to 64)
MilestoneDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
Started302301
Completed209219
Not completed9382
Withdrew: Adverse event109
Withdrew: Death11
Withdrew: Extension phase eligibility failure due to week 12 laboratory values20
Withdrew: Lack of efficacy22
Withdrew: Lost to follow-up1913
Withdrew: Non-compliance1514
Withdrew: Physician decision99
Withdrew: Pregnancy22
Withdrew: Protocol deviation23
Withdrew: Sponsor recommendation10
Withdrew: Withdrawal by subject2928
Withdrew: Other than specified11
Follow-up Phase (up to 72 Weeks)
Participant flow — Follow-up Phase (up to 72 Weeks)
MilestoneDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
Started332336
Completed267274
Not completed6562
Withdrew: Not reported4948
Withdrew: Lost to follow-up106
Withdrew: Non-compliance21
Withdrew: Withdrawal by subject47

Outcome measures

PrimaryChange From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase

A migraine day: any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache: a migraine with or without aura, lasting for ≥30 minutes, and meeting at least 1 of the following criteria (a and/or b): a) ≥2 of the following: unilateral location, pulsating quality, moderate to severe pain intensity, aggravation by or causing avoidance of routine physical activity; b) ≥1 of the following: nausea and/or vomiting, photophobia, and phonophobia. If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the last 4 weeks of the DBT phase (Weeks 9 to 12) minus number of monthly migraine days during the OP.

Time frame:
OP and Weeks 9 to 12 of the DBT phase
Reported as:
Least squares mean · Total Migraine Days per Month
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase
Total Migraine Days per MonthRimegepant - Randomization PhasePlacebo - Randomization Phase
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase-4.3 (-4.83 to -3.87)-3.5 (-4 to -3.04)
Statistical analysis
  • Rimegepant - Randomization Phase vs Placebo - Randomization Phase · Mixed Models Analysis · p = 0.0099 · Mean difference (final values): -0.8 · 95% CI -1.46 to -0.20
SecondaryNumber of Participants Who Had ≥ 50% Reduction in Moderate or Severe Migraine Days Per Month in the Last 4 Weeks of the DBT Phase

A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. A moderate or severe migraine day was a migraine day of moderate or severe pain intensity. Months were defined as 28-day intervals. A reduction of at least 50% in the mean number of moderate or severe monthly migraine days was determined if the number of moderate or severe monthly migraine days in the last 4 weeks of the DBT (Weeks 9 to 12) was less than or equal to half (50%) of the number of moderate or severe monthly migraine days in the OP.

Time frame:
OP and Weeks 9 to 12 of the DBT phase
Reported as:
Number · percentage of participants
Number of Participants Who Had ≥ 50% Reduction in Moderate or Severe Migraine Days Per Month in the Last 4 Weeks of the DBT Phase
percentage of participantsRimegepant - Randomization PhasePlacebo - Randomization Phase
Number of Participants Who Had ≥ 50% Reduction in Moderate or Severe Migraine Days Per Month in the Last 4 Weeks of the DBT Phase49.1 (43.9 to 54.3)41.5 (36.3 to 46.7)
Statistical analysis
  • Rimegepant - Randomization Phase vs Placebo - Randomization Phase · Cochran-Mantel-Haenszel · p = 0.0438 · Risk difference (rd): 7.6 · 95% CI 0.2 to 14.9
SecondaryChange From Baseline in the Mean Number of Migraine Days Per Month Over the Entire Course of the DBT Phase

A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the DBT phase (Weeks 1 to 12) minus the number of monthly migraine days during the OP.

Time frame:
OP and Weeks 1 to 12 of the DBT phase
Reported as:
Least squares mean · Total Migraine Days per Month
Change From Baseline in the Mean Number of Migraine Days Per Month Over the Entire Course of the DBT Phase
Total Migraine Days per MonthRimegepant - Randomization PhasePlacebo - Randomization Phase
Change From Baseline in the Mean Number of Migraine Days Per Month Over the Entire Course of the DBT Phase-3.6 (-3.97 to -3.17)-2.7 (-3.14 to -2.34)
Statistical analysis
  • Rimegepant - Randomization Phase vs Placebo - Randomization Phase · Mixed Models Analysis · p = 0.0017 · Mean difference (net): -0.8 · 95% CI -1.34 to -0.31
SecondaryFrequency of Use of Rescue Medication Days Per Month in the Last Month of the DBT Phase

A rescue medication day was a day on which the participant took triptan, ergotamine, or other permitted medication to acutely treat headache or aura. Months were defined as 28-day intervals.

Time frame:
Weeks 9 to 12 of the DBT phase
Reported as:
Least squares mean · rescue medication Days per Month
Frequency of Use of Rescue Medication Days Per Month in the Last Month of the DBT Phase
rescue medication Days per MonthRimegepant - Randomization PhasePlacebo - Randomization Phase
Frequency of Use of Rescue Medication Days Per Month in the Last Month of the DBT Phase3.7 (3.29 to 4.15)4.0 (3.53 to 4.39)
Statistical analysis
  • Rimegepant - Randomization Phase vs Placebo - Randomization Phase · Mixed Models Analysis · p = 0.3868 (P-value ≥ 0.05; therefore, all secondary endpoints listed after this endpoint in the hierarchy were not tested.) · Mean difference (net): -0.2 · 95% CI -0.80 to 0.31
SecondaryChange From Baseline in the Mean Number of Total Migraine Days Per Month in the First Month of the DBT Phase

A migraine day was any calendar day in which the participant experienced a qualified migraine headache (as previously described). If the participant took a migraine-specific medication during aura or to treat headache on a calendar day, it was counted as a migraine day regardless of the duration and pain features/associated symptoms. Months were defined as 28-day intervals. The change from baseline was calculated as the number of monthly migraine days during the first 4 weeks of the DBT phase (Weeks 1 to 4) minus the number of monthly migraine days during the OP.

Time frame:
OP and Weeks 1 to 4 of the DBT phase
Reported as:
Least squares mean · migraine days per month
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the First Month of the DBT Phase
migraine days per monthRimegepant - Randomization PhasePlacebo - Randomization Phase
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the First Month of the DBT Phase-2.9 (-3.32 to -2.46)-1.7 (-2.15 to -1.29)
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation in the DBT Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

Time frame:
Weeks 1 to 12 of the DBT phase
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation in the DBT Phase
ParticipantsRimegepant - Randomization PhasePlacebo - Randomization Phase
AEs133133
SAEs34
AEs leading to study drug discontinuation74
SecondaryNumber of Participants With AEs, SAEs, AEs Leading to Study Drug Discontinuation in the OLE Phase

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition on-treatment in a patient or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was defined as any event that met any of the following criteria: death; life-threatening; inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received rimegepant; other important medical events that may not have resulted in death, be life-threatening, or required hospitalization, based upon appropriate medical judgment, they may have jeopardized the participant and may have required medical or surgical intervention.

Time frame:
OLE Phase (Weeks 13 through 64)
Reported as:
Count of participants · Participants
Number of Participants With AEs, SAEs, AEs Leading to Study Drug Discontinuation in the OLE Phase
ParticipantsDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
AEs150162
SAEs76
AEs leading to study drug discontinuation98
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities in the DBT Phase

Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in Common Technical Criteria for Adverse Events (CTCAE) Version 5.0 (2017) if available; otherwise, according to Division of Acquired Immune Deficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the DBT phase to be included for a given parameter.

Time frame:
Weeks 1 to 12 of the DBT phase
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities in the DBT Phase
ParticipantsRimegepant - Randomization PhasePlacebo - Randomization Phase
Eosinophils00
Hemoglobin01
Lymphocytes, high00
Lymphocytes, low00
Neutrophils42
Platelets10
White Blood Cells10
Alanine Aminotransferase (ALT)10
Aspartate Aminotransferase (AST)10
Albumin00
Alkaline Phosphatase00
Bicarbonate00
Bilirubin00
Calcium, high00
Calcium, low00
Cholesterol00
Creatine Kinase44
Creatinine00
Glucose, high00
Glucose, low00
LDL-cholesterol20
LDL-cholesterol, fasting00
LDL-cholesterol, not fasting20
Lactate Dehydrogenase00
Potassium, high12
Potassium, low00
Sodium, high00
Sodium, low00
Triglycerides00
Triglycerides, fasting00
Triglycerides, not fasting00
Uric acid00
Glomerular Filtration Rate, Estimated10
Urine Glucose00
Urine Protein10
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities in the OLE Phase

Clinically significant laboratory abnormalities were defined as Grade 3 to 4 laboratory test results according to numeric laboratory test criteria found in CTCAE Version 5.0 (2017) if available; otherwise, according to DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 (2017) for glucose, LDL-cholesterol, uric acid, and urinalysis. Laboratory test groups of clinical interest included hematology, serum chemistry, and urinalysis. Participants must have had a non-missing measurement in the OLE phase to be included for a given parameter.

Time frame:
OLE Phase (Weeks 13 through 64)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities in the OLE Phase
ParticipantsDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
Eosinophils00
Hemoglobin11
Lymphocytes, high00
Lymphocytes, low10
Neutrophils11
Platelets00
White Blood Cells00
Alanine Aminotransferase (ALT)05
Aspartate Aminotransferase (AST)13
Albumin00
Alkaline Phosphatase00
Bicarbonate00
Bilirubin00
Calcium, high00
Calcium, low00
Cholesterol00
Creatine Kinase47
Creatinine00
Glucose, high00
Glucose, low01
LDL-cholesterol55
LDL-cholesterol, fasting23
LDL-cholesterol, not fasting32
Lactate Dehydrogenase00
Potassium, high20
Potassium, low00
Sodium, high00
Sodium, low00
Triglycerides32
Triglycerides, fasting01
Triglycerides, not fasting32
Uric acid00
Glomerular Filtration Rate, Estimated00
Urine Glucose00
Urine Protein00
SecondaryNumber of Participants With Elevations of AST or ALT > 3 x Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) > 2 x ULN During the DBT Phase

Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the OLE phase to be included.

Time frame:
Weeks 1 to 12 of the DBT phase
Reported as:
Number · Percentage of participants
Number of Participants With Elevations of AST or ALT > 3 x Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) > 2 x ULN During the DBT Phase
Percentage of participantsRimegepant - Randomization PhasePlacebo - Randomization Phase
Number of Participants With Elevations of AST or ALT > 3 x Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) > 2 x ULN During the DBT Phase0 (0.00 to 1.24)0 (0.00 to 1.24)
SecondaryPercentage of Participants With Elevations of AST or ALT > 3 x ULN Concurrent With TBL > 2 x ULN During the OLE Phase

Elevations of AST or ALT \> 3 x ULN concurrent with TBL \> 2 x ULN were defined as elevations on the same collection date. Participants must have had a non-missing AST, ALT, or TBL measurement in the DBT phase to be included.

Time frame:
OLE Phase (Weeks 13 through 64)
Reported as:
Number · Percentage of participants
Percentage of Participants With Elevations of AST or ALT > 3 x ULN Concurrent With TBL > 2 x ULN During the OLE Phase
Percentage of participantsDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
Percentage of Participants With Elevations of AST or ALT > 3 x ULN Concurrent With TBL > 2 x ULN During the OLE Phase0 (0.00 to 1.51)0 (0.00 to 1.52)
SecondaryNumber of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the DBT Phase

Hepatic AEs were defined as all preferred terms in the DBT phase under the "Hepatic Disorders" Standardized Medical Dictionary (Version 21.1) for Regulatory Activities Query (SMQ), except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.

Time frame:
Weeks 1 to 12 of the DBT phase
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the DBT Phase
ParticipantsRimegepant - Randomization PhasePlacebo - Randomization Phase
Hepatic-related AE62
Severe hepatic-related AE00
Hepatic-related SAE00
Hepatic-related AE leading to study drug discontinuation22
SecondaryNumber of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the OLE Phase

Hepatic AEs were defined as all preferred terms in the OLE phase under the "Hepatic Disorders" SMQ, except those preferred terms in the "Congenital, Familial, Neonatal and Genetic Disorders of the Liver" SMQ.

Time frame:
OLE Phase (Weeks 13 through 64)
Reported as:
Count of participants · Participants
Number of Participants With Hepatic-related AEs and Hepatic-related AEs Leading to Discontinuation During the OLE Phase
ParticipantsDBT Rimegepant/OL RimegepantDBT Placebo/OL Rimegepant
Hepatic-related AE29
Severe hepatic-related AE01
Hepatic-related SAE00
Hepatic-related AE leading to study drug discontinuation11
SecondaryMean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase

The Migraine Specific Quality of Life (MSQoL) is a self-administered, 14-item instrument that has been validated in 3 domains: role restriction, role prevention, and the emotional function. The role function-restrictive domain consists of 7 items that describe how migraine limits one's daily social and work-related activities. Participants respond to items using a 6-point scale: "none of the time," "a little bit of the time," "some of the time," "a good bit of the time," "most of the time," and "all of the time," which are assigned scores of 1 to 6, respectively. Item scores are recoded using (7 - original score). Next, raw dimension scores are computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that higher scores indicate better quality of life. The change from baseline was calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.

Time frame:
Baseline, Week 12 of the DBT Phase
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase
score on a scaleRimegepant - Randomization PhasePlacebo - Randomization Phase
Mean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase18.0 (15.54 to 20.56)14.6 (12.07 to 17.10)
SecondaryMean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase

The Migraine Disability Assessment (MIDAS) is a retrospective, self-administered, 5-item questionnaire that measures headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provide the number of missed work or school days; missed household chores days; missed social or leisure activity days; and days at work or school, and separately at home, where productivity was reduced by half or more in the last 3 months (scale: 0 - 90 for each of 5 subscales). The 5 subscale scores are summed to compute the MIDAS total score (scale: 0 - 450). Lower scores indicate less headache-related disability. The change from baseline was calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.

Time frame:
Baseline, Week 12 of the DBT Phase
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase
Scores on a scaleRimegepant - Randomization PhasePlacebo - Randomization Phase
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase-11.8 (-15.41 to -8.21)-11.7 (-15.29 to -8.10)

Adverse events

Collected over DBT Phase: From the first dose in the DBT Phase (Week 1) to Week 12 OLE Phase: Week 13 to Week 64 Follow-up phase: 8 weeks after the end of treatment (maximum duration of treatment: 64 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rimegepant - Randomization Phase0/370 (0%)3/370 (0.8%)0/370 (0%)
Placebo - Randomization Phase0/371 (0%)4/371 (1.1%)0/371 (0%)
DBT Rimegepant/OLE Rimegepant - OLE Phase1/302 (0.3%)7/302 (2.3%)41/302 (13.6%)
DBT Placebo/OLE Rimegepant - OLE Phase1/301 (0.3%)6/301 (2%)37/301 (12.3%)
DBT Rimegepant/OLE Rimegepant - Follow-up Phase0/332 (0%)2/332 (0.6%)41/332 (12.3%)
DBT Placebo/OLE Rimegepant - Follow-up Phase0/336 (0%)2/336 (0.6%)34/336 (10.1%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventRimegepant - Randomization PhasePlacebo - Randomization PhaseDBT Rimegepant/OLE Rimegepant - OLE PhaseDBT Placebo/OLE Rimegepant - OLE PhaseDBT Rimegepant/OLE Rimegepant - Follow-up PhaseDBT Placebo/OLE Rimegepant - Follow-up Phase
Abdominal pain lowerGastrointestinal disorders0/3700/3710/3021/3010/3320/336
ColitisGastrointestinal disorders0/3700/3710/3021/3010/3320/336
DiverticulitisInfections and infestations0/3700/3711/3021/3010/3320/336
Urinary tract infectionInfections and infestations0/3700/3710/3021/3010/3320/336
Myocardial infarctionCardiac disorders0/3700/3710/3021/3010/3320/336
Back painMusculoskeletal and connective tissue disorders0/3700/3710/3021/3010/3320/336
Aortic dissectionVascular disorders0/3700/3710/3021/3010/3320/336
Gastric ulcerGastrointestinal disorders0/3700/3711/3020/3010/3320/336
Gastrooesophageal reflux diseaseGastrointestinal disorders0/3700/3711/3020/3010/3320/336
Septic shockInfections and infestations0/3700/3711/3020/3010/3320/336
Most frequent other events
Most frequent other events
EventRimegepant - Randomization PhasePlacebo - Randomization PhaseDBT Rimegepant/OLE Rimegepant - OLE PhaseDBT Placebo/OLE Rimegepant - OLE PhaseDBT Rimegepant/OLE Rimegepant - Follow-up PhaseDBT Placebo/OLE Rimegepant - Follow-up Phase
NasopharyngitisInfections and infestations0/3700/37123/30215/30123/33215/336
Upper respiratory tract infectionInfections and infestations0/3700/37121/30222/30121/33219/336

Baseline characteristics

Participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Rimegepant - Randomization PhasePlacebo - Randomization PhaseTotal
Mean41.3 ± 13.0141.1 ± 13.1341.2 ± 13.06
Sex: Female, Male
Sex: Female, Male(Participants)Rimegepant - Randomization PhasePlacebo - Randomization PhaseTotal
Female300313613
Male7058128
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rimegepant - Randomization PhasePlacebo - Randomization PhaseTotal
Hispanic or Latino10598203
Not Hispanic or Latino265273538
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rimegepant - Randomization PhasePlacebo - Randomization PhaseTotal
American Indian or Alaska Native617
Asian178
Native Hawaiian or Other Pacific Islander033
Black or African American6249111
White295309604
More than one race628
Unknown or Not Reported000
08

Study locations

93 sites
  • MDFirst Research-Chandler
    Chandler, Arizona 85286, United States
  • MedPharmics, LLC
    Phoenix, Arizona 85015, United States
  • Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Axiom Research, LLC
    Apple Valley, California 92307, United States
  • Axiom Research, LLC
    Colton, California 92324, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Optimus Medical Group
    San Francisco, California 94102, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • California Neuroscience Research Medical Group
    Sherman Oaks, California 91403, United States
  • Ki Health Partners, LLC, dba New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Galiz Research
    Hialeah, Florida 33016, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Qps Mra, Llc
    Miami, Florida 33143, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33155, United States
  • Harmony Clinical Research
    North Miami Beach, Florida 33162, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • JSV Clinical Research Study Inc.
    Tampa, Florida 33634, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Northwest Clinical Trials, Inc
    Boise, Idaho 83704, United States
  • R&R Clinical Research
    Idaho Falls, Idaho 83404, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Family Medicine Specialists/CIS
    Wauconda, Illinois 60084, United States
  • Community Clinical Research Center
    Anderson, Indiana 46011, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • Phoenix Medical Research
    Prairie Village, Kansas 66208, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Crescent City Headache and Neurology Center
    Chalmette, Louisiana 70043, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • DelRicht Research
    New Orleans, Louisiana 70124, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • ActivMed Practices & Research, Inc.
    Methuen, Massachusetts 01844, United States
  • Regeneris Medical
    North Attleboro, Massachusetts 02760, United States
  • Michigan Head Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Michigan Pain Consultants
    Grand Rapids, Michigan 49503, United States
  • MedPharmics, LLC
    Biloxi, Mississippi 39531, United States
  • Clinical Research Professionals, Inc.
    Chesterfield, Missouri 63005, United States
  • The Center for Pharmaceutical Research, LLC
    Kansas City, Missouri 64114, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Quality Clinical Research, Inc
    Omaha, Nebraska 68114, United States
  • Nevada Headache Institute
    Las Vegas, Nevada 89113, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Albuquerque Neuroscience, Inc.
    Albuquerque, New Mexico 87109, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Mid Hudson Medical Research, PLLC
    New Windsor, New York 12553, United States
  • Island Neurological, A Division of Prohealth Care Associates, LLP
    Plainview, New York 11803, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • PharmQuest, LLC
    Greensboro, North Carolina 27408, United States
  • PMG Research
    Raleigh, North Carolina 27609, United States
  • Carolina Research Institute Center, Inc.
    Shelby, North Carolina 28150, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Hometown Urgent Care
    Cincinnati, Ohio 45215, United States
  • Hometown Urgent Care and Research
    Dayton, Ohio 45424, United States
  • Neurology Diagnostics Research
    Dayton, Ohio 45459, United States
  • Aventiv Research, Inc
    Dublin, Ohio 43016, United States
  • Oklahoma Headache Center
    Norman, Oklahoma 73072, United States
  • Tekton Research
    Yukon, Oklahoma 73099, United States
  • Summit Research Network (Oregon) Inc.
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
    Salem, Oregon 97301, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • BTC of Lincoln, LLC
    Lincoln, Rhode Island 02865, United States
  • OnSite Clinical Solutions
    Dillon, South Carolina 29536, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Meridian Clinical Research
    Dakota Dunes, South Dakota 57049, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Ventavia Research Group, LLC
    Fort Worth, Texas 76104, United States
  • North Texas Institute of Neurology & Headache
    Frisco, Texas 75034, United States
  • Victorium Clinical Research
    Houston, Texas 77024, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • Red Star Research, LLC
    Lake Jackson, Texas 77566, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • Victorium Clinical Research
    San Antonio, Texas 78230, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Wasatch Clinical Research, LLC
    Salt Lake City, Utah 84107, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • MedStar Georgetown Headache - Georgetown University
    McLean, Virginia 22102, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Seattle Women's
    Seattle, Washington 98105, United States
  • Clinical Investigation Specialists, Inc.
    Kenosha, Wisconsin 53144, United States
09

References and documents

Publications

  • Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15. Erratum In: Lancet. 2024 Jun 15;403(10444):2596. doi: 10.1016/S0140-6736(24)01208-X. PubMed 33338437 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2019, 12 months.

Results were first posted in Aug 2021, 1 year 7 months after primary completion. A results delay was requested in Nov 2020.

Of 12 phase 2/3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2018
First posted
Nov 6, 2018
StartActual
Nov 14, 2018
Primary completionActual
Dec 10, 2019
CompletionActual
Feb 2, 2021
Results delay requested
Nov 24, 2020
Results first posted
Aug 9, 2021
Last update
Jun 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03732638
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 6, 2018
Start date
Nov 14, 2018
Primary completion
Dec 10, 2019
Completion
Feb 2, 2021
Results posted
Aug 9, 2021
Last update
Jun 7, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion